magnetic stimulation therapy
Recently Published Documents


TOTAL DOCUMENTS

45
(FIVE YEARS 5)

H-INDEX

6
(FIVE YEARS 0)

2021 ◽  
Author(s):  
Takuro Kobayashi ◽  
Toshiyuki China ◽  
Naoko Takazawa ◽  
Fumitaka Shimizu ◽  
Julius Fink ◽  
...  

Pelvic bottom dysfunction includes sexual dysfunction, lower urinary tract dysfunction, defecation dysfunction, etc., and the quality of daily life is significantly impaired. Although drug based and surgical therapies exist as treatment methods, non-invasive treatment methods for pelvic floor dysfunction are highly desired, and magnetic stimulation therapy is attracting attention as a potential new approach. Magnetic stimulation therapy can generate deeper stimulations as compared to electrical stimulation therapy, is less painful, and can be performed while wearing clothes. In addition, it is a very safe treatment method with only few reports of side effects. From nocturnal enuresis in children to middle-aged sexual dysfunction and urinary incontinence in the elderly, therapeutic effects on various pelvic floor dysfunctions have been confirmed regardless of age and gender. It is expected that magnetic therapy will continue to develop as a new therapy in the futures. This chapter first describes the pelvic floor muscles and the principles of anatomy and magnetic therapy. In addition, the therapeutic effects of magnetic therapy will be explained in detail one by one. We will also explain the potential application of magnetic therapy for sarcopenia, which is a problem in our aging society.



2021 ◽  
pp. 000486742110430
Author(s):  
Paul B Fitzgerald ◽  
Mark S George ◽  
Saxby Pridmore

Despite more than 25 years of research establishing the antidepressant efficacy of repetitive transcranial magnetic stimulation, there remains uncertainty about the depth and breadth of this evidence base, resulting in confusion as to where repetitive transcranial magnetic stimulation fits in the therapeutic armamentarium in the management of patients with mood disorders. The purpose of this article is to provide a concise description of the evidence base supporting the use of repetitive transcranial magnetic stimulation in the context of the stages of research that typically accompanies the development of evidence for a new therapy. The antidepressant efficacy for the use of repetitive transcranial magnetic stimulation in the treatment of depression has been established through a relatively traditional pathway beginning with small case series, progressing to single-site clinical trials and then to larger multisite randomised double-blind controlled trials. Antidepressant effects have been confirmed in numerous meta-analyses followed more recently by large network meta-analysis and umbrella reviews, with evidence that repetitive transcranial magnetic stimulation may have greater efficacy than alternatives for patients with treatment-resistant depression. Finally, repetitive transcranial magnetic stimulation has been shown to produce meaningful response and remission rates in real-world samples of greater than 5000 patients. The evidence for the antidepressant efficacy of repetitive transcranial magnetic stimulation therapy is overwhelming, and it should be considered a routine part of clinical care wherever available.





BMJ Open ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. e038557
Author(s):  
Siqian Zhong ◽  
Yiru Hu ◽  
Yu Fu ◽  
Liping Cao ◽  
Bin Zhang

IntroductionSchizophrenia is a psychiatric illness associated with brain function alterations and varying degree of treatment resistance, often leading to severe social malfunctioning. In recent decades, numerous studies have been investigating the therapeutic potential of transcranial magnetic stimulation (TMS) as a non-invasive therapy for schizophrenia. However, its clinical efficacy remains controversial, as a number of clinical trials indicated moderate therapeutic effect while others failed to reproduce the positive result. Moreover, the neurobiological mechanism of action remains unclear, possibly constricting the application of TMS in clinical practice. The present protocol of meta-analysis aims to investigate the TMS-related functional neuroimaging (ie, functional MRI) features and alterations in subjects with schizophrenia, and to discuss the potential of functional MRI in TMS researches.Methods and analysisThe study selection process will follow the Preferred Reporting Items for Meta-Analyses guideline and quality assessment will be conducted with a customised checklist. We plan to search in the following databases: PubMed, Embase, OVID, China National Knowledge Infrastructure and Wanfang Data, from their respective dates of inception to 1 May 2020, with language restricted to English and Chinese. Studies focusing on the brain functional alterations in patients with schizophrenia treated by TMS will be retrieved.Ethics and disseminationThis work does not require ethics approval as it will be based on published studies. This systematic review will be publicly disseminated in peer-reviewed journals.PROSPERO registration numberCRD42020166288.



BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e038099
Author(s):  
Yongyan Deng ◽  
Wenyue Li ◽  
Bin Zhang

IntroductionAs a prevalent psychiatric disease, depression is a life-threatening mental disorder that may cause work disability and premature death. Transcranial magnetic stimulation (TMS) is a non-invasive neuromodulation procedure, which has been reported to have a significant effect on antidepressant treatment in recent years. However, the parameters of TMS for depression that can produce the best clinical benefits remain unknown. In the present study, we will evaluate the effect of TMS treatment for depression from the perspective of functional neuroimaging by performing a meta-analysis based on included studies.Methods and analysisTwo independent reviewers will search published studies in the following five databases: PubMed, Web of Science, Embase, China National Knowledge Infrastructure and WANGFANG DATA from inception to 1 June 2020. Then we will select studies according to predesigned inclusion and exclusion criteria. After extracting data from included studies, activation likelihood estimation will be applied to data synthesis. Any disagreement will be checked by the third reviewer who will also make the final decision.Ethics and disseminationThis work does not require ethics approval as it will be based on published studies. This review will be published in peer-reviewed journals.PROSPERO registration numberCRD42020165436.



2020 ◽  
Vol 10 (7) ◽  
pp. 423
Author(s):  
Manuel F. Casanova ◽  
Mohamed Shaban ◽  
Mohammed Ghazal ◽  
Ayman S. El-Baz ◽  
Emily L. Casanova ◽  
...  

Autism spectrum disorder (ASD) is a behaviorally diagnosed neurodevelopmental condition of unknown pathology. Research suggests that abnormalities of elecltroencephalogram (EEG) gamma oscillations may provide a biomarker of the condition. In this study, envelope analysis of demodulated waveforms for evoked and induced gamma oscillations in response to Kanizsa figures in an oddball task were analyzed and compared in 19 ASD and 19 age/gender-matched neurotypical children. The ASD group was treated with low frequency transcranial magnetic stimulation (TMS), (1.0 Hz, 90% motor threshold, 18 weekly sessions) targeting the dorsolateral prefrontal cortex. In ASD subjects, as compared to neurotypicals, significant differences in evoked and induced gamma oscillations were evident in higher magnitude of gamma oscillations pre-TMS, especially in response to non-target cues. Recordings post-TMS treatment in ASD revealed a significant reduction of gamma responses to task-irrelevant stimuli. Participants committed fewer errors post-TMS. Behavioral questionnaires showed a decrease in irritability, hyperactivity, and repetitive behavior scores. The use of a novel metric for gamma oscillations. i.e., envelope analysis using wavelet transformation allowed for characterization of the impedance of the originating neuronal circuit. The results suggest that gamma oscillations may provide a biomarker reflective of the excitatory/inhibitory balance of the cortex and a putative outcome measure for interventions in autism.



Sign in / Sign up

Export Citation Format

Share Document